82278-99-7

Usage

Uses

Used in Pharmaceutical Research:
DL-N-(TERT-BUTOXYCARBONYL)-3-METHOXYPHENYLALANINE is used as a building block for the synthesis of peptides and other organic compounds. The Boc protecting group is crucial in preventing unwanted reactions at the amino group during peptide synthesis, ensuring the desired product is obtained.
Used in Organic Chemistry:
In the field of organic chemistry, DL-N-(TERT-BUTOXYCARBONYL)-3-METHOXYPHENYLALANINE is used as a precursor for the development of complex organic molecules. The methoxy group provides additional steric hindrance and electronic effects, which can be beneficial in the synthesis of specific target compounds.
Used in Peptide Synthesis:
DL-N-(TERT-BUTOXYCARBONYL)-3-METHOXYPHENYLALANINE is used as a protected amino acid in peptide synthesis. The Boc protecting group allows chemists to selectively incorporate this amino acid into peptide chains without unwanted side reactions, which is essential for creating well-defined peptide-based drugs and bioactive compounds.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 

Relevant academic research and scientific papers

INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS

Provided herein are compounds that modulate the activity of melanoma inhibitor of apoptosis (ML-IAP) protein, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

INHIBITORS OF AKT ACTIVITY

Invented are novel 1 H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure

A series of peptidomimetic human immunodeficiency virus (HIV) protease inhibitors containing substituted allophenylnorstatine [Apns: (2S,3S)-3-amino-2-hydroxy-4-phenylbutyric acid] were designed and synthesized. From the structure-metabolism relationship of this type of HIV protease inhibitors, the compounds having para substitution of the phenyl ring of Apns and/or 2,6-disubstitution of the P2′ benzylamine were found to be able to avoid the P2 phenol glucuronidation that occurs with SM-319777 (formerly named JE-2147, KNI-764); one of the main metabolic pathways of SM-319777. These new analogues, such as SM-322377, had more desirable pharmacokinetic profiles and more potent antiviral activity against not only wild type HIV-1 but also the multi-drug-resistant HIV-1 than SM-319777.